设计,合成和生物评估阿洛林衍生物作为潜在的抗癌剂
Tian-Tian Zhao1, Long-Ying Shen1, Yu Cheng1
1State Key Laboratory of Bioactive Substance and Function of Natural Medicines and Beijing Key Laboratory of Active Substances Discovery and Druggability Evaluation, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.
Journal of Asian natural products research
|June 26, 2024
概括
研究人员修改了阿洛佩林分子,制造出新的抗癌药物. 一系列新的化合物,特别是化合物22,通过诱导癌细胞的亡和细胞循环停止,显示出显著的抗癌活性.
科学领域:
- 药用化学 医学化学
- 药理学 药理学是指药理学的学科.
- 药物发现 药物发现 药物发现
背景情况:
- 素是一种天然产品,已显示出潜在的抗癌特性.
- 对天然产品架构的修改是药物开发中的一个常见策略.
- 优化抗癌活性需要了解结构-活性关系.
研究的目的:
- 合成和评估新型阿洛佩林衍生物,以改善抗癌活性.
- 为了建立一个结构-活性关系的阿洛氨酸修饰.
- 确定用于进一步抗癌药物开发的化合物.
主要方法:
- 44种新型阿洛佩林衍生物的合成.
- 在实验室中对抗癌细胞系的抗癌活性进行评估.
- 基于修改位置的结构-活动关系分析.
- 作用机制研究包括细胞亡和细胞循环分析.
主要成果:
- 一系列的阿洛林硫尿素衍生物被合成.
- 与阿洛林相比,在N12位置修改的化合物表现出增强的细胞毒性.
- 化合物22在PC9细胞 (IC50 = 1.43μM) 上表现出强大的体外抗癌活性.
- 化合物22诱导PC9细胞的亡和细胞循环停止.
结论:
- 修改阿洛佩林,特别是在N12位置,可以显著增强抗癌性质.
- 化合物22是抗癌药物开发的有希望的首选药物.
- 氨酸氨酸衍生物具有开发新型抗癌疗法的潜力.
更多相关视频
相关概念视频
Structure-Activity Relationships and Drug Design
697
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
697
Drug Discovery: Overview
7.8K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.8K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
158
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
158
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
2.8K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
2.8K


